Search Results
Results found for "Neel Freedman"
- Why Mastering Pharmacokinetics Fundamentals Still Defines Discovery Success Today
integration —from scaffold design through population modeling— correlates with clinical success Scientists need
- GPCR Binding Affinity Experiments: Interpreting Data With Confidence as We Head Into 2026
GPCR Premium Membership Gives You an Edge Premium Membership is designed for scientists and teams who need
- Chemical Drug Matter : Rethinking the Molecules We Choose to Develop In Drug Discovery
method-proven insight for discovery teams, pharmacologists refining core skills, and R&D leads who need
- The Truth About GPCR Product Launches: Years in the Making
dose-response with Exendin-4 on GLP-1 receptors—and saw clean, plate-based internalization curves without needing
- The Five Traps of Ignoring Kinetics
you actually use in discovery A growing on-demand library of lessons you can revisit whenever you need
- What's Going On with GPCRs?! Find Out in This Week's Update! ⦿ Nov 4 - 10, 2024
This strategic decision to limit free content is essential as we need to increase revenue to support
- Understanding Enzyme Inhibition In GPCR Discovery Programs
GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need
- Targeting GPCRs in the CNS: Advances in Drug Discovery Strategies
their targets are on the membrane of cells, they have easier access to the receptors than those that need
- Decoding β-Arrestins: from Structure to function
question of whether β-arrestin1 and 2 serve overlapping or distinct functions remains, raising the need Nonetheless, there is an ongoing need to delve deeper into the intricate mechanisms governing GPCR activation
- Why Opposing Processes Matter for Your Next GPCR Drug
section raises a critical design question for teams Are you sure your “antagonist” is enough—or do you need
- Quantifying Receptor Selectivity in Modern Drug Discovery
Terry Kenakin, monthly live AMAs, and a growing on-demand library built for scientists who need clarity
- 📰 GPCR Weekly News, July 24 to July 30, 2023
Science Crinetics Hosting Key Opinion Leader Webinar To Discuss The Current Treatment Landscape And Unmet Need
- GPCR Collaboration: From Models to Medicine
It also allows Carlsson to stay plugged into the fast-changing needs of biotech while keeping his academic
- Discover the Hottest GPCR News of the Week: Oct 7-13, 2024!
Dynamic Learning Environment Tailored to Your Needs Maximize your learning experience by accessing our
- Beyond Clearance: The Strategic Power of Irreversible Drug Binding
Dose prediction models need kinetic nuance—not just Cmax and AUC.
- 📰 GPCR Weekly News, September 18 to 24, 2023
You don't need to be registered to participate.
- Unlocking the Future of Medicine: Advancements in GPCR Research
Feel free to reach out to us at Hello@DrGPCR.com.
- 📰 GPCR Weekly News, January 8 to 14, 2024
Registrations are open to everyone (you will need to become a free site member) and end on February 1st
- VAMP2: a crucial player in the delivery of MOR to the synapse
been well characterized, the mechanisms that modulate the delivery of GPCRs to the membrane cell still need
- 📰 GPCR Weekly News, January 1 to 7, 2024
Registrations are open to everyone (you will need to become a free site member) and end on February 1st
- 📰 Breaking Down the Latest GPCR Discoveries: a Weekly Update (Nov 27-Dec 3, 2023)
Neil Grimsey and Dr. Katarzyna Marcinkiewicz.
- 📰 GPCR Weekly News, November 20 to 26, 2023
Neil Grimsey and Dr. Katarzyna Marcinkiewicz.
- 📰 GPCR Weekly News, April 22 to 28, 2024
Mark has experience connecting candidates with employers and will work with you to understand your needs
- 📰 GPCR Weekly News, April 15 to 21, 2024
Mark has experience connecting candidates with employers and will work with you to understand your needs
- Orthosteric Binding Experiments: How to Avoid the Most Common Data Pitfalls
for pharmacologists strengthening fundamentals, program teams navigating bottlenecks, and leaders who need
- Chemokine receptor-targeted drug discovery: progress and challenges
feature of the chemokine system (Nedjai et al. 2012), but more research in different cellular contexts is needed
- From Failed Experiments to Predictive GPCR Models
commercial compound libraries, the work inevitably reaches a point where novel, non-commercial ligands are needed
- Enzyme Inhibition Pharmacology: The Hidden Gatekeepers of GPCR Drug Discovery
in mindset (seeing enzymes as predictable, targetable, quantifiable systems ) is exactly what teams need
- A2A Fluorescent Competitive Binding: Advancing NanoBRET® Target Engagement for GPCR Drug Discovery
They are needed to identify the best concentrations for each tool.
- GPCRs are not simple on-off switches: deep dive into GPCR-ligand interactions
opioid receptors were shown to constitutively activate Gi proteins in a membrane preparation without the need




















